Omnicell (NASDAQ:OMCL) Rating Lowered to “Hold” at StockNews.com

Omnicell (NASDAQ:OMCL) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

A number of other analysts also recently weighed in on OMCL. Benchmark reiterated a “buy” rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Barclays boosted their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Bank of America restated a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Finally, Wells Fargo & Company increased their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday, October 14th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $50.83.

Omnicell Trading Down 2.0 %

NASDAQ OMCL opened at $45.67 on Friday. The company has a market cap of $2.12 billion, a price-to-earnings ratio of -117.10, a PEG ratio of 46.03 and a beta of 0.81. The company has a 50 day moving average of $44.20 and a 200-day moving average of $36.82. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently made changes to their positions in OMCL. Victory Capital Management Inc. lifted its stake in Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after purchasing an additional 1,138,921 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after acquiring an additional 909,480 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Omnicell during the 3rd quarter valued at $32,721,000. Pacer Advisors Inc. grew its position in Omnicell by 32.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after acquiring an additional 508,789 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after acquiring an additional 259,463 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.